In CRC, A-to-I editing of BLCAP by ADAR2 leads to a substitution from glutamine to proline at residue 5, accelerating degradation of BLCAP via the ubiquitination-proteasome pathway (Han et al., 2022). Here, ADARB1 is linked to colorectal carcinoma.